8-KEarnings & ResultsExhibits & Filings

Merck & Co., Inc. 8-K Report, Financial Results (Feb 4, 2021)

Filed February 4, 2021For Securities:MRK

Summary

Merck & Co., Inc. (MRK) filed an 8-K on February 4, 2021, to report its fourth quarter and full-year 2020 financial results. The filing incorporates by reference a press release (Exhibit 99.1) and supplemental information (Exhibit 99.2) detailing these results. While the 8-K itself doesn't contain the specific financial figures, it serves as the official notification and means of accessing the detailed earnings report provided by the company. Investors should refer to the attached Exhibits 99.1 and 99.2 for the actual financial performance data. This includes key metrics such as revenue, net income, earnings per share, and any forward-looking guidance provided by Merck for the upcoming periods. The report is crucial for understanding the company's recent financial health and its outlook.

Key Highlights

  • 1Filing of 8-K on February 4, 2021, for Merck & Co., Inc. (MRK).
  • 2Reports financial results for the fourth quarter and full year ended December 31, 2020.
  • 3Incorporates by reference a press release (Exhibit 99.1) detailing the earnings.
  • 4Includes supplemental information not present in the press release (Exhibit 99.2).
  • 5Securities registered on the NYSE include Common Stock (MRK) and various notes due in 2021, 2024, 2026, 2034, and 2036.
  • 6Information furnished under Item 2.02 is not deemed 'filed' for Section 18 of the Exchange Act.
  • 7Exhibit 104 contains the Cover Page Interactive Data File.

Frequently Asked Questions

The main purpose of this 8-K filing is to officially report Merck & Co., Inc.'s financial results for the fourth quarter and the full year of 2020. It serves as a notification to investors and incorporates by reference the detailed press release and supplemental information containing the actual financial data.

The specific financial results are detailed in Exhibit 99.1 (the press release) and Exhibit 99.2 (certain supplemental information), which are incorporated by reference into this 8-K filing. Investors should review these exhibits for detailed figures on revenue, earnings, and other key financial metrics.

While the 8-K filing itself does not contain the guidance, the incorporated press release (Exhibit 99.1) and supplemental information (Exhibit 99.2) often include forward-looking statements and financial guidance from the company for future periods. Investors should examine these attached documents for any outlook provided by Merck.

According to the filing, the information furnished under Item 2.02 is not deemed 'filed' for purposes of Section 18 of the Securities Exchange Act of 1934, nor is it generally incorporated by reference into other filings unless specifically stated. This means it doesn't carry the same level of legal liability as formally filed reports.